ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,821 to 3,840 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Absorb BVS vs XIENCE: Number of Participants With All Myocardial Infarction (MI)159 of 1,187

69 of 612

2.1 points

-1.2 to 5.2

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Cardiac Death/TV-MI/ID-TLR (TLF)220 of 1,187

98 of 612

2.5 points

-1.2 to 6.1

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Participants With All Target Vessel Revascularization (TVR) Excluding Target Lesion Revascularization (TLR)108 of 1,187

40 of 612

2.6 points

-0.1 to 5.0

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)245 of 1,187

113 of 612

2.2 points

-1.8 to 5.9

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Death/All MI230 of 1,187

101 of 612

2.9 points

-0.9 to 6.5

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Intervention vs Baseline Period: Percentage of Cases Who Received Excessive Post-procedural Antimicrobials216 of 525

644 of 1,272

-9.5 points

-14.4 to -4.4

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline Period: Percentage of Cases Who Received a Late Antimicrobial Prescription83 of 525

169 of 1,272

2.5 points

-1.0 to 6.3

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline Period: Percentage of Cases Who Underwent Clostridioides Difficile Testing1 of 525

6 of 1,272

-0.3 points

-0.9 to 0.6

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline Period: Percentage of Cases Who Died (Mortality)4 of 525

4 of 1,272

0.4 points

-0.2 to 1.6

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline: deaths from any cause4 of 525

4 of 1,272

0.4 points

-0.2 to 1.6

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline Period: Percentage of Cases Who Were Re-admitted to the Hospital or Presented to an Emergency Department or an Urgent Care Clinic113 of 525

186 of 1,272

6.9 points

3.0 to 11.0

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Intervention vs Baseline: serious adverse events113 of 525

186 of 1,272

6.9 points

3.0 to 11.0

1,797NCT04196777

Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists

Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 180 Days Post Vaccination12 of 1,198

6 of 598

-0.0 points

-1.2 to 0.9

1,796NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting New Onset Chronic Diseases From Administration of Investigational Product Through 180 Days Post Vaccination11 of 1,198

4 of 598

0.2 points

-0.9 to 1.1

1,796NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs All FluMist: The Number of Participants Reporting Any Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination210 of 1,198

118 of 598

-2.2 points

-6.2 to 1.5

1,796NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs All FluMist: Number of Participants Reporting Any Serious Adverse Event From Administration of Investigational Product Through 28 Days Post Vaccination2 of 1,198

2 of 598

-0.2 points

-1.1 to 0.3

1,796NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs All FluMist: serious adverse events12 of 1,198

6 of 598

-0.0 points

-1.2 to 0.9

1,796NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV-BFS (MEDI8662) vs All FluMist: serious adverse events15 of 1,198

2 of 596

0.9 points

-0.1 to 1.8

1,794NCT00952705

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

Everolimus vs Placebo: deaths from any cause112 of 896

119 of 896

-0.8 points

-3.9 to 2.3

1,792NCT01674140

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Arm 1 vs Arm 2: Secondary Endpoint283 of 899

312 of 892

-3.5 points

-7.8 to 0.9

1,791NCT00032487

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=192"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=192

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01751906-a83e4582",
        "title": "Absorb BVS vs XIENCE: Number of Participants With All Myocardial Infarction (MI)",
        "summary": "159 of 1187 against 69 of 612; risk difference 2.1 points, 95% interval -1.2 to 5.2; NCT01751906, ABSORB III Randomized Controlled Trial (RCT)",
        "record": "/library/comparisons/NCT01751906-a83e4582",
        "nct_id": "NCT01751906",
        "kind": "outcome",
        "participants": 1799,
        "risk_difference": {
          "value": 0.021206039281761555,
          "lower": -0.011780932197695972,
          "upper": 0.05181963144111174
        },
        "group_1": "159 of 1,187",
        "group_2": "69 of 612",
        "difference": "2.1 points",
        "interval": "-1.2 to 5.2",
        "trial_title": "ABSORB III Randomized Controlled Trial (RCT)"
      },
      {
        "id": "NCT01751906-befd7054",
        "title": "Absorb BVS vs XIENCE: Number of Cardiac Death/TV-MI/ID-TLR (TLF)",
        "summary": "220 of 1187 against 98 of 612; risk difference 2.5 points, 95% interval -1.2 to 6.1; NCT01751906, ABSORB III Randomized Controlled Trial (RCT)",
        "record": "/library/comparisons/NCT01751906-befd7054",
        "nct_id": "NCT01751906",
        "kind": "outcome",
        "participants": 1799,
        "risk_difference": {
          "value": 0.025210477338927728,
          "lower": -0.012410135555592915,
          "upper": 0.06068918302004261
        },
        "group_1": "220 of 1,187",
        "group_2": "98 of 612",
        "difference": "2.5 points",
        "interval": "-1.2 to 6.1",
        "trial_title": "ABSORB III Randomized Controlled Trial (RCT)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=193",
  "request_id": "r0aPmT0zuLHj1StO"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?